NO944914D0 - Fremgangsmåte for å inhibere autoimmunsykdommer - Google Patents

Fremgangsmåte for å inhibere autoimmunsykdommer

Info

Publication number
NO944914D0
NO944914D0 NO944914A NO944914A NO944914D0 NO 944914 D0 NO944914 D0 NO 944914D0 NO 944914 A NO944914 A NO 944914A NO 944914 A NO944914 A NO 944914A NO 944914 D0 NO944914 D0 NO 944914D0
Authority
NO
Norway
Prior art keywords
autoimmune diseases
inhibiting autoimmune
inhibiting
diseases
autoimmune
Prior art date
Application number
NO944914A
Other languages
English (en)
Other versions
NO944914L (no
Inventor
Steven Harold Zuckerman
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO944914D0 publication Critical patent/NO944914D0/no
Publication of NO944914L publication Critical patent/NO944914L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
NO944914A 1993-12-21 1994-12-19 Fremgangsmåte for å inhibere autoimmunsykdommer NO944914L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/170,608 US5521198A (en) 1993-12-21 1993-12-21 Methods of inhibiting autoimmune diseases

Publications (2)

Publication Number Publication Date
NO944914D0 true NO944914D0 (no) 1994-12-19
NO944914L NO944914L (no) 1995-06-22

Family

ID=22620579

Family Applications (1)

Application Number Title Priority Date Filing Date
NO944914A NO944914L (no) 1993-12-21 1994-12-19 Fremgangsmåte for å inhibere autoimmunsykdommer

Country Status (15)

Country Link
US (2) US5521198A (no)
EP (1) EP0664123A1 (no)
JP (1) JPH07215855A (no)
KR (1) KR950016723A (no)
CN (1) CN1108102A (no)
AU (1) AU699255B2 (no)
CA (1) CA2138509A1 (no)
CZ (1) CZ320694A3 (no)
HU (1) HUT71327A (no)
IL (1) IL112031A (no)
NO (1) NO944914L (no)
NZ (1) NZ270164A (no)
PH (1) PH31599A (no)
RU (1) RU94044454A (no)
ZA (1) ZA9410083B (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6197789B1 (en) 1995-06-07 2001-03-06 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US5596106A (en) * 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
US5434166A (en) * 1994-08-22 1995-07-18 Eli Lilly And Company Methods of inhibiting demyelinating and desmyelinating diseases
US5545641A (en) * 1994-10-20 1996-08-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of bradykinin
CZ246597A3 (cs) * 1995-02-06 1998-06-17 Eli Lilly And Company Použití sloučeniny k přípravě terapeutického přípravku pro inhibici účinku interleukinu 6, účinků faktoru inhibice leukemie a inhibici systému povrchového receptoru
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US5985932A (en) * 1996-02-28 1999-11-16 Pfizer Inc Inhibition of autoimmune diseases
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
WO1998046588A2 (en) 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6008232A (en) * 1997-08-20 1999-12-28 Eli Lilly And Company Methods for preventing headaches
HUP0203437A3 (en) 1999-03-22 2003-07-28 Immugen Pharmaceuticals Inc So Use of resorcinol derivatives for producing pharmaceutical compositions for treatment of immune diseases
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
ATE301129T1 (de) 1999-05-04 2005-08-15 Strakan Int Ltd Androgen glykoside und die androgenische aktivität davon
AU2002213429A1 (en) * 2000-09-28 2002-04-08 Immugen Pharmaceuticals, Inc. Antiviral methods and compounds
AU2001296402A1 (en) * 2000-09-28 2002-04-08 Immugen Pharmaceuticals, Inc. Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation
US20030232101A1 (en) * 2002-03-18 2003-12-18 Immugen Pharmaceuticals, Inc. Topical formulations of resorcinols and cannibinoids and methods of use
JP3887588B2 (ja) * 2002-08-30 2007-02-28 株式会社リガク X線回折による応力測定法
CN1723013A (zh) * 2003-01-06 2006-01-18 惠氏公司 雌激素受体α调节剂在治疗多发性硬化症中的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
AU5286693A (en) * 1992-10-27 1994-05-24 Nippon Kayaku Kabushiki Kaisha Use of non steroidal anti estrogens for autoimmune diseases
JP4111352B2 (ja) 1996-05-21 2008-07-02 新日鐵住金ステンレス株式会社 ステンレス鋼の高清浄化精錬法

Also Published As

Publication number Publication date
PH31599A (en) 1998-11-03
AU699255B2 (en) 1998-11-26
ZA9410083B (en) 1996-06-19
US5521198A (en) 1996-05-28
CN1108102A (zh) 1995-09-13
RU94044454A (ru) 1996-10-10
HU9403658D0 (en) 1995-02-28
HUT71327A (en) 1995-11-28
NZ270164A (en) 1997-08-22
CZ320694A3 (en) 1995-09-13
CA2138509A1 (en) 1995-06-22
IL112031A (en) 1999-12-22
KR950016723A (ko) 1995-07-20
JPH07215855A (ja) 1995-08-15
US6436958B1 (en) 2002-08-20
IL112031A0 (en) 1995-03-15
NO944914L (no) 1995-06-22
AU8153794A (en) 1995-06-29
EP0664123A1 (en) 1995-07-26

Similar Documents

Publication Publication Date Title
NO944914D0 (no) Fremgangsmåte for å inhibere autoimmunsykdommer
NO973009D0 (no) Fremgangsmåte for å inhibere kathepsin-k
NO960339D0 (no) Fremgangsmåte for å inhibere restenose
NO953043D0 (no) Fremgangsmåte for syntetisere acetotriglyceridfett
DK42093D0 (da) Administrationsmetode
ATE230981T1 (de) Verfahren
NO943761D0 (no) Oralt administrerbare opioide formuleringer med forlenget effektvarighet
HU9403657D0 (en) Methods of inhibiting pulmonary hypertenzive diseases
NO975761L (no) Fremgangsmåte for å inhibere hydratdannelse
NO975589L (no) Fremgangsmåte for å inhibere hydratdannelse
NO975668L (no) Fremgangsmåte for å forhindre hydratdannelse
NO944926D0 (no) Fremgangsmåter for å inhibere myeloperoksidase-aktivitet
NO944931D0 (no) Anvendelse av 2-fenyl-3-arroylbenzotiofener for inhibering av tidlig seksuell modenhet
NO975580D0 (no) Fremgangsmåte for å inhibere melanom
NO943748D0 (no) Fremgangsmåte for å isomerisere 2-metyl-3-buten-nitril
NO975699D0 (no) Fremgangsmåte for oksyklorering
NO973609D0 (no) Fremgangsmåte for å inhibere effektene av IL-6
MX9206026A (es) Procedimiento de alquilacion de isoalcan-olefinas
NO944909D0 (no) Fremgangsmåter for inhibering av mannlig infertilitet
FI943989A0 (fi) Terapeuttisia tai ehkäiseviä aineita peroksilipidiin liittyviin sairauksiin
DK36193D0 (da) Fremgangsmaade
NO940806D0 (no) Fremgangsmåte for å syntentisere urea
ID918B (id) Proses pembuatan vinir
KR950004860U (ko) 조립식 오디오용 플러그
SG64924A1 (en) Inhibiting photodecompostion of 3-substituted-2- oxindoles